RO7823653 Clinical Trials (2026): 1 Studies for Diabetic Macular Edema

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

1 RO7823653 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Diabetic Macular Edema) and 93 total planned enrollment. 1 RO7823653 clinical trial is actively recruiting at 8 U.S. sites across 6 states. Most recent activity: NCT07425522 (Nov 2028).

Where to Participate: All RO7823653 Trial Sites in the U.S. (8 sites across 6 states)

Every actively recruiting RO7823653trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZAssociated Retina Consultants - Peoria - DocTrials - PPDSPeoria85381-3690NCT07425522Map
CARetina-Vitreous Associates Medical GroupBeverly Hills90211-1838NCT07425522Map
FLRetina Vitreous Associates of FloridaSt. Petersburg33711-1141NCT07425522Map
PAErie Retina Research, LLC - 300 State StErie16507-1429NCT07425522Map
TXRetina Research Institute of TexasAbilene79606-1224NCT07425522Map
TXAustin Clinical Research, LLCAustin78750-2298NCT07425522Map
TXRetina Consultants of Texas Westover Hills Retina CenterSan Antonio78251NCT07425522Map
VAPiedmont Eye CenterLynchburg24502-4271NCT07425522Map

RO7823653 clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P111

Recruiting RO7823653 clinical trials (1)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07425522DMEA Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)P1Diabetic Macular Edema93Apr 2026

All RO7823653 trials (1)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07425522DMEA Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)P1recruiting93Genentech, Inc.Apr 2026

RO7823653 clinical trials: frequently asked questions

How many RO7823653 clinical trials are there?
1 RO7823653 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
Are RO7823653 clinical trials recruiting in 2026?
Yes — 1 RO7823653 trial is actively recruiting in 2026, with 8 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
What conditions is RO7823653 being studied for?
RO7823653 is being studied for Diabetic Macular Edema. The trials are grouped by indication on this page.
What phase is RO7823653 in?
RO7823653 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors RO7823653 clinical trials?
The lead sponsor across the most RO7823653 trials is Genentech, Inc.. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming RO7823653as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: